Ray Dorsey
Ray Dorsey is a physician and researcher working in the field of neurology. His research primarily focuses on Parkinson's disease, covering primary prevention strategies, environmental risk factors, and patient-centered care models. Additionally, his work explores the application of digital health technologies, wearable sensors, and remote AI-based screening tools for neurodegenerative conditions.
49 claims checked on air: 5 context 1 overstated 31 supported 12 unverified
What they said on air - unverified
2 citing their own research
Golf courses use up to 80 times more pesticide per acre than agricultural areas.
"So, golf courses are huge consumers of pesticides, up to 80 times as much of pesticide per acre than agricultural areas." (said at 0:00:15)
A systematic search across academic literature indices did not identify any published studies or empirical datasets demonstrating that golf courses apply up to 80 times more pesticide per acre than agricultural land. While turfgrass management on golf courses (particularly on greens and fairways) involves intensive chemical inputs including fungicides and insecticides, comparative per-acre application rates vary substantially across specific agricultural crops and turf management systems, and no peer-reviewed record corroborating an 80-fold difference was found. This lack of published verification does not prove the claim false, but means the specific figure remains unverified.
Paraquat use in the United States doubled over the 5 most recent publicly reported years from the US Geological Survey and tripled over an eight-year period.
"According to reporting from Carey Gillam, I think tripled amount of use in the last eight years; according to the US Geological Survey, doubling the amount of use in the last five years for which data are publicly available." (said at 0:13:35)
A search of scholarly records indexed in OpenAlex did not yield peer-reviewed publications containing the specific numerical figures reported by journalist Carey Gillam regarding US Geological Survey (USGS) agricultural pesticide use data (specifically, that annual paraquat use doubled over a 5-year period and tripled over an 8-year period). While USGS National Water-Quality Assessment (NAWQA) data track agricultural pesticide applications in the United States, the exact statistics stated could not be verified directly from the retrieved peer-reviewed literature.
A cluster of eight to nine individuals, including Mary Tidwell, developed Parkinson's disease on 27th Street in Sioux Falls, South Dakota, adjacent to agricultural cornfields.
"Ms. Mary Tidwell shared with me this map. And this is of 27th Street in Sioux Falls, South Dakota, which these homes were built on top of a former cornfield. And there was a cornfield still next to the street. And Ms. Tidwell developed Parkinson's disease, as did seven or eight other people on her street in South Dakota." (said at 0:19:09)
No published epidemiological study, outbreak investigation, or peer-reviewed case report was located documenting a Parkinson's disease cluster on 27th Street in Sioux Falls, South Dakota, or involving Mary Tidwell. While personal reports and anecdotal accounts of geographic clusters are sometimes described by patients or advocates, this specific residential cluster has not been formally verified or documented in indexed scientific literature.
Twenty percent of common foods contain detectable residues of pesticides.
"Yeah. So, um 20% of common foods have residues of pesticides." (said at 0:29:54)
No published surveillance report or peer-reviewed study matching the specific claim that exactly '20% of common foods have residues of pesticides' was identified in the searched records. While national monitoring efforts like the USDA Pesticide Data Program (PDP) and the FDA Pesticide Residue Monitoring Program track residues across hundreds of thousands of food samples, detection rates vary substantially by commodity type, farming practice (conventional vs. organic), and year, typically showing detectable residues in a much higher proportion of conventional fresh produce (often exceeding 50% to 70%), with the vast majority remaining well below established EPA safety tolerances.
When the federal government measures pesticide residues on produce like apples, testing is conducted after the produce has been held under running water for 15 to 20 seconds.
"And when the federal government determines whether measures the residue of a pesticide, for example, in an apple, they do so after it's held under water for 15 to 20 seconds." (said at 0:29:59)
Although the USDA's Pesticide Data Program (PDP) is widely documented as monitoring pesticide residues on consumer produce using standardized laboratory sample preparation protocols designed to mimic consumer handling, no peer-reviewed journal articles in the fetched database records contained the specific textual description of the sample preparation protocol (e.g., holding produce under running tap water for 15 to 20 seconds). This does not prove the claim false, as specific testing standard operating procedures are typically detailed in agency technical manuals and SOP documentation rather than journal abstracts.
Quitting cigarette smoking reduces the risk of heart disease within one year and halves the risk of lung cancer within ten years.
"Just like you stop smoking a cigarette, within a year your risk of heart disease is down; within 10 years, the risk of lung cancer is is halved." (said at 0:36:40)
No published records could be fetched and reviewed within the search limit to verify the specific quantitative risk reduction milestones (cardiovascular risk decrease within one year and halving of lung cancer risk within ten years). This does not prove the claim false, as these timelines are widely cited benchmarks in public health literature (such as reports by the U.S. Surgeon General and WHO), but direct verification against fetched abstracts was not completed.
Golf courses use up to 80 times as much pesticide per acre of land compared to agricultural farms.
"So, golf courses are huge consumers of pesticides. Up to 80 times as much pesticide per acre of land than farms." (said at 0:43:43)
A systematic search of scholarly literature indexed in OpenAlex did not identify peer-reviewed publications establishing or corroborating the claim that golf courses use 'up to 80 times as much pesticide per acre of land' compared to agricultural farms. While popular reporting and advocacy reports sometimes compare turfgrass chemical application intensities to conventional agricultural acreage, verified academic sources documenting an application intensity discrepancy of this specific magnitude were not retrieved.
Carl Robb, who lived adjacent to a golf course fairway and worked on its maintenance sod squad as a teenager, was diagnosed with Parkinson's disease at age 23.
"Beginning at age 10, Carl Robb, a tech entrepreneur, lived in suburban Charlotte, North Carolina, right next to the 13th hole... As a teenager, Carl was looking for a summer job and joined the golf course's sod squad... He saw nine doctors over six years before being diagnosed with Parkinson's at age 23." (said at 0:47:49)
No published medical case report or peer-reviewed study documenting Carl Robb's specific clinical history (living adjacent to a golf course fairway, working on the maintenance sod squad, and being diagnosed with Parkinson's disease at age 23) was located in the PubMed or Europe PMC databases. While this personal narrative appears in popular books and advocacy literature on environmental risk factors and Parkinson's disease, it has not been documented as an indexed scientific case report. This does not prove the biographical account false, but means it cannot be verified against the peer-reviewed scientific literature.
Four out of one hundred people who worked on the Canadian sitcom 'Leo and Me' with Michael J. Fox developed early-onset Parkinson's disease.
"And what's also been recorded in the New York Times is that he was part of a cluster of people with Parkinson's: four of the hundred people who worked on his TV show, the sitcom Leo and Me, a Canadian sitcom before Family Ties, developed Parkinson's, all at an early age." (said at 0:53:47)
No published epidemiological study, outbreak investigation, or peer-reviewed medical case series was identified in PubMed or Europe PMC documenting a confirmed cluster of early-onset Parkinson's disease among the cast and crew of the Canadian television production 'Leo and Me'. While media reports (such as in The New York Times in 2002) discussed an investigation into four individuals associated with the production who developed Parkinson's disease, the claim cannot be verified against the peer-reviewed medical literature.
A published study has linked green space workers to an increased risk of developing amyotrophic lateral sclerosis (ALS).
"There's one study linking green space workers to ALS." (said at 0:53:59)
No published study specifically evaluating occupational 'green space workers' and risk of amyotrophic lateral sclerosis (ALS) was identified. Published literature in this domain has instead investigated residential exposure to green space (which found a non-linear U-shaped association with ALS risk in a Northern Italian population-based case-control study, PMID: 42169130) and avocational gardening or pesticide exposure (PMID: 38591179, PMID: 24979055). The claim appears to conflate residential green space exposure or avocational gardening with an occupational cohort of green space workers.
Three epidemiological studies (in Italy, Spain, and Scotland) have linked professional soccer playing to an increased risk of ALS.
"And then as you mentioned, there are three studies—one in Italy, one in Spain, I believe, and one in Scotland—linking soccer players to ALS." (said at 0:54:34)
No published records could be fetched within the tool limit to verify the specific details across the three cited cohort studies (Italy, Spain, and Scotland). While published epidemiological studies have evaluated ALS incidence in Italian professional soccer players (e.g., Chiò et al., 2005) and Scottish former professional footballers (e.g., the FIELD study), no matching abstracts were retrieved and read in this session to confirm the findings for all three countries.
One in three 85-year-olds will develop Alzheimer's disease.
"There are reasons why one in three 85-year-olds will get Alzheimer's disease." (said at 1:02:35)
No matching published epidemiological records confirming or refuting the exact stated statistic (that one in three 85-year-olds will develop Alzheimer's disease) were successfully retrieved within the search budget. Although epidemiological reports (such as the Alzheimer's Association Facts and Figures) commonly cite that roughly one-third (approx. 32–33%) of individuals aged 85 and older have Alzheimer's dementia, a specific published record verifying the claim could not be fetched here.
Fact-checked episodes
Publications
- Preventive Neurology Isn't a Pill; It's a Plan.JAMA neurology 2026 · CEBM Level 5
- The Parkinson's Universe: A person-centered care model for Parkinson's disease.Journal of Parkinson's disease 2026 · CEBM Level 5
- The Parkinson's Disease-Health Index: A novel, disease-specific patient-reported outcome measure.Journal of Parkinson's disease 2026 · CEBM Level 4
- Validation of remote multimodal AI screening for Parkinson disease across diverse settings.Communications medicine 2026 · CEBM Level 3
- Primary prevention of Parkinson's disease: proceedings, the 8C's and a position statement from the Parkinson's disease prevention think tank.NPJ Parkinson's disease 2026 · CEBM Level 5
- Patient-Reported Symptom Burden in Individuals With Parkinson Disease.Neurology. Clinical practice 2026 · CEBM Level 4
- Slow-SPEED: protocol for three randomised trials of remotely delivered exercise to prevent Parkinson's disease.NPJ Parkinson's disease 2026 · CEBM Level 5
- A paradoxical plus for Parkinson's in UK's new 'generational smoking ban'.Journal of Parkinson's disease 2026 · CEBM Level 5
- Stage-specific digital health technology biomarkers enhance diagnostic and early progression detection in Parkinson's disease.Frontiers in neurology 2026 · CEBM Level 3
- Longitudinal qualitative assessment of meaningful symptoms and relevance of WATCH-PD digital measures for people with early Parkinson's.Journal of neurology 2025 · CEBM Level 3
- Using wearable sensors and machine learning to assess upper limb function in Huntington's disease.Communications medicine 2025 · CEBM Level 4
- Proximity to Golf Courses and Risk of Parkinson Disease.JAMA network open 2025 · CEBM Level 4
- Remote AI Screening for Parkinson's Disease: A Multimodal, Cross-Setting Validation Study.Research square 2025 · CEBM Level 3
- Stable two-year longitudinal clinical outcomes in LRRK2 G2019S non-manifest carriers in a remote nationwide study.Parkinsonism & related disorders 2025 · CEBM Level 3
- Improving Prediction of Falls and Cognitive Impairment in Parkinson Disease: Protocol for a Decentralized Observational Study.JMIR research protocols 2025 · CEBM Level 5
- Trichloroethylene and Parkinson Disease.Neurology 2025 · CEBM Level 5
- Environmental toxicants and Parkinson's disease: recent evidence, risks, and prevention opportunities.The Lancet. Neurology 2025 · CEBM Level 5
- A PLAN to address the Parkinson pandemic.Journal of Parkinson's disease 2025 · CEBM Level 5
- Locally adapting digital health technologies to address the global challenge of Parkinson's disease.Equity neuroscience 2025 · CEBM Level 5
- Parkinson's Disease Is Predominantly an Environmental Disease.Journal of Parkinson's disease 2024 · CEBM Level 5
- Digital assessment of speech in Huntington disease.Frontiers in neurology 2024 · CEBM Level 4
- Dry-Cleaning Chemicals and a Cluster of Parkinson's Disease and Cancer: A Retrospective Investigation.Movement disorders : official journal of the Movement Disorder Society 2024 · CEBM Level 4
- The Prevalence of Parkinson's Disease in Poland: Regional and Sex-Related Differences.Journal of Parkinson's disease 2024 · CEBM Level 4
- Improved measurement of disease progression in people living with early Parkinson's disease using digital health technologies.Communications medicine 2024 · CEBM Level 3
- Parkinson's Disease in Sub-Saharan Africa: Pesticides as a Double-Edged Sword.Journal of Parkinson's disease 2024 · CEBM Level 5
- The Body, the Brain, the Environment, and Parkinson's Disease.Journal of Parkinson's disease 2024 · CEBM Level 5
- Using a smartwatch and smartphone to assess early Parkinson's disease in the WATCH-PD study over 12 months.NPJ Parkinson's disease 2024 · CEBM Level 3
- Using Wearable Sensors and Machine Learning to Assess Upper Limb Function in Huntington's Disease.Research square 2024 · CEBM Level 4
- Genetic modifiers of somatic expansion and clinical phenotypes in Huntington's disease reveal shared and tissue-specific effects.bioRxiv : the preprint server for biology 2024 · CEBM Level 4
- Wearable Sensor-Based Assessments for Remotely Screening Early-Stage Parkinson's Disease.Sensors (Basel, Switzerland) 2024 · CEBM Level 4
- Education Research: Observational Study of Educational Debt Among US Medical Graduates Entering Neurology, 2010-2021.Neurology. Education 2024 · CEBM Level 4
- Return of individual research results to participants with and at risk for Parkinson's disease.Journal of clinical and translational science 2024 · CEBM Level 4
- Caring for an invisible population - those with advanced Parkinson's disease.Parkinsonism & related disorders 2023 · CEBM Level 5
- Retraction Note: Facial expressions can detect Parkinson's disease: preliminary evidence from videos collected online.NPJ digital medicine 2023 · CEBM Level 5
- Paraquat, Parkinson's Disease, and Agnotology.Movement disorders : official journal of the Movement Disorder Society 2023 · CEBM Level 5
- Trichloroethylene: An Invisible Cause of Parkinson's Disease?Journal of Parkinson's disease 2023 · CEBM Level 5
- Using a smartwatch and smartphone to assess early Parkinson's disease in the WATCH-PD study.NPJ Parkinson's disease 2023 · CEBM Level 4
- The Water, the Air, the Marines-Camp Lejeune, Trichloroethylene, and Parkinson Disease.JAMA neurology 2023 · CEBM Level 5
- Relative Meaningfulness and Impacts of Symptoms in People with Early-Stage Parkinson's Disease.Journal of Parkinson's disease 2023 · CEBM Level 4
- Mapping Relevance of Digital Measures to Meaningful Symptoms and Impacts in Early Parkinson's Disease.Journal of Parkinson's disease 2023 · CEBM Level 4
- Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design.Movement disorders : official journal of the Movement Disorder Society 2023 · CEBM Level 3
- Unsupervised anomaly detection by densely contrastive learning for time series data.Neural networks : the official journal of the International Neural Network Society 2023 · CEBM Level 5
- Towards interpretable speech biomarkers: exploring MFCCs.Scientific reports 2023 · CEBM Level 4
- Remote smartphone monitoring of Parkinson's disease and individual response to therapy.Nature biotechnology 2022 · CEBM Level 3
- Preventing Parkinson's Disease: An Environmental Agenda.Journal of Parkinson's disease 2022 · CEBM Level 5
- Recruitment for Remote Decentralized Studies in Parkinson's Disease.Journal of Parkinson's disease 2022 · CEBM Level 4
- A Smartphone Application as an Exploratory Endpoint in a Phase 3 Parkinson's Disease Clinical Trial: A Pilot Study.Digital biomarkers 2022 · CEBM Level 3
- Genetic modifiers of Huntington disease differentially influence motor and cognitive domains.American journal of human genetics 2022 · CEBM Level 4
- Metadata Framework to Support Deployment of Digital Health Technologies in Clinical Trials in Parkinson's Disease.Sensors (Basel, Switzerland) 2022 · CEBM Level 5
- The Huntington's Disease Health Index: Initial Evaluation of a Disease-Specific Patient Reported Outcome Measure.Journal of Huntington's disease 2022 · CEBM Level 4
- Six Action Steps to Address Global Disparities in Parkinson Disease: A World Health Organization Priority.JAMA neurology 2022 · CEBM Level 5
- Identifying and characterising sources of variability in digital outcome measures in Parkinson's disease.NPJ digital medicine 2022 · CEBM Level 5
- A Remote Longitudinal Observational Study of Individuals at Genetic Risk for Parkinson Disease: Baseline Results.Neurology. Genetics 2022 · CEBM Level 4
- Artificial intelligence-enabled detection and assessment of Parkinson's disease using nocturnal breathing signals.Nature medicine 2022 · CEBM Level 3
- Monitoring gait at home with radio waves in Parkinson's disease: A marker of severity, progression, and medication response.Science translational medicine 2022 · CEBM Level 3
- Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study.JAMA neurology 2021 · CEBM Level 3
- Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD).Annals of clinical and translational neurology 2021 · CEBM Level 4
- Using Technology to Reshape Clinical Care and Research in Parkinson's Disease.Journal of Parkinson's disease 2021 · CEBM Level 5
- The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism.NPJ Parkinson's disease 2021 · CEBM Level 5
- Development of digital measures for nighttime scratch and sleep using wrist-worn wearable devices.NPJ digital medicine 2021 · CEBM Level 4
- Crowdsourcing digital health measures to predict Parkinson's disease severity: the Parkinson's Disease Digital Biomarker DREAM Challenge.NPJ digital medicine 2021 · CEBM Level 4
- Improving Access to Care: Telemedicine Across Medical Domains.Annual review of public health 2021 · CEBM Level 5
- GEORGE®: A Pilot Study of a Smartphone Application for Huntington's Disease.Journal of Huntington's disease 2021 · CEBM Level 4
- Practicing in a Pandemic: A Clinician's Guide to Remote Neurologic Care.Neurology. Clinical practice 2021 · CEBM Level 5
- The triple aim of clinical research.Clinical trials (London, England) 2021 · CEBM Level 5
- Bad Air and Parkinson Disease-The Fog May Be Lifting.JAMA neurology 2021 · CEBM Level 5
- Parkinson disease risks: correctly identifying environmental factors for a chronic disease.The Journal of clinical investigation 2021 · CEBM Level 5
- The new platforms of health care.NPJ digital medicine 2021 · CEBM Level 5
- Video-based Parkinson's disease assessments in a nationwide cohort of Fox Insight participants.Clinical parkinsonism & related disorders 2021 · CEBM Level 4
- Facial expressions can detect Parkinson's disease: preliminary evidence from videos collected online.NPJ digital medicine 2021 · CEBM Level 4
- Seeking progress in disease modification in Parkinson disease.Parkinsonism & related disorders 2021 · CEBM Level 5
- Detecting Parkinson Disease Using a Web-Based Speech Task: Observational Study.Journal of medical Internet research 2021 · CEBM Level 4
- Digital Endpoints: Definition, Benefits, and Current Barriers in Accelerating Development and Adoption.Digital biomarkers 2021 · CEBM Level 5
- A real-world study of wearable sensors in Parkinson's disease.NPJ Parkinson's disease 2021 · CEBM Level 4
- Quadruple Decision Making for Parkinson's Disease Patients: Combining Expert Opinion, Patient Preferences, Scientific Evidence, and Big Data Approaches to Reach Precision Medicine.Journal of Parkinson's disease 2020 · CEBM Level 5
- A Longitudinal Wearable Sensor Study in Huntington's Disease.Journal of Huntington's disease 2020 · CEBM Level 3
- Telemedicine 2020 and the next decade.Lancet (London, England) 2020 · CEBM Level 5
- Video research visits for atypical parkinsonian syndromes among Fox Trial Finder participants.Neurology. Clinical practice 2020 · CEBM Level 4
- Symptom burden among individuals with Parkinson disease: A national survey.Neurology. Clinical practice 2020 · CEBM Level 4
- Patient-reported impact of symptoms in Huntington disease: PRISM-HD.Neurology 2020 · CEBM Level 4
- The Coronavirus Disease 2019 Crisis as Catalyst for Telemedicine for Chronic Neurological Disorders.JAMA neurology 2020 · CEBM Level 5
- A digital health industry cohort across the health continuum.NPJ digital medicine 2020 · CEBM Level 4
- Deep Phenotyping of Parkinson's Disease.Journal of Parkinson's disease 2020 · CEBM Level 5
- Integrated and patient-centred management of Parkinson's disease: a network model for reshaping chronic neurological care.The Lancet. Neurology 2020 · CEBM Level 5
- Care, Convenience, Comfort, Confidentiality, and Contagion: The 5 C's that Will Shape the Future of Telemedicine.Journal of Parkinson's disease 2020 · CEBM Level 5
- Genotyping single nucleotide polymorphisms for allele-selective therapy in Huntington disease.Neurology. Genetics 2020 · CEBM Level 4
- A Virtual Cohort Study of Individuals at Genetic Risk for Parkinson's Disease: Study Protocol and Design.Journal of Parkinson's disease 2020 · CEBM Level 5
- Current and projected future economic burden of Parkinson's disease in the U.S.NPJ Parkinson's disease 2020 · CEBM Level 4
- Remote Administration of the MDS-UPDRS in the Time of COVID-19 and Beyond.Journal of Parkinson's disease 2020 · CEBM Level 5
- The New Normal in Clinical Trials: Decentralized Studies.Annals of neurology 2020 · CEBM Level 5
- A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders.Movement disorders : official journal of the Movement Disorder Society 2020 · CEBM Level 5
- Feasibility, Reliability, and Value of Remote Video-Based Trial Visits in Parkinson's Disease.Journal of Parkinson's disease 2020 · CEBM Level 3
- Patient-centred management of Parkinson's disease - Authors' reply.The Lancet. Neurology 2020 · CEBM Level 5
- Direct-to-consumer digital health.The Lancet. Digital health 2020 · CEBM Level 5
- Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science.Digital biomarkers 2020 · CEBM Level 5
- Multidisciplinary care for people with Parkinson's disease: the new kids on the block!Expert review of neurotherapeutics 2019 · CEBM Level 5
- Top-Funded Digital Health Companies And Their Impact On High-Burden, High-Cost Conditions.Health affairs (Project Hope) 2019 · CEBM Level 4
- Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI).Parkinsonism & related disorders 2019 · CEBM Level 3
- The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age.Movement disorders : official journal of the Movement Disorder Society 2019 · CEBM Level 5
- A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies.Movement disorders : official journal of the Movement Disorder Society 2019 · CEBM Level 5
- Patient Views on Telemedicine for Parkinson Disease.Journal of Parkinson's disease 2019 · CEBM Level 4
- Cost vs care.Neurology 2019 · CEBM Level 5
- Passive Monitoring at Home: A Pilot Study in Parkinson Disease.Digital biomarkers 2019 · CEBM Level 4
- A New Chapter.Digital biomarkers 2019 · CEBM Level 5
- Advancing the Use of Mobile Technologies in Clinical Trials: Recommendations from the Clinical Trials Transformation Initiative.Digital biomarkers 2019 · CEBM Level 5
- The Parkinson Pandemic-A Call to Action.JAMA neurology 2018 · CEBM Level 5
- Telemedicine for Parkinson's Disease: Limited Engagement Between Local Clinicians and Remote Specialists.Telemedicine journal and e-health : the official journal of the American Telemedicine Association 2018 · CEBM Level 4
- Telemedicine Use for Movement Disorders: A Global Survey.Telemedicine journal and e-health : the official journal of the American Telemedicine Association 2018 · CEBM Level 4
- Using Smartphones and Machine Learning to Quantify Parkinson Disease Severity: The Mobile Parkinson Disease Score.JAMA neurology 2018 · CEBM Level 3
- Teleneurology and mobile technologies: the future of neurological care.Nature reviews. Neurology 2018 · CEBM Level 5
- The State of US Health, 1990-2016: Burden of Diseases, Injuries, and Risk Factors Among US States.JAMA 2018 · CEBM Level 3
- Medical Education and the Public Service Loan Forgiveness Program: Unnecessary Uncertainties.Annals of internal medicine 2018 · CEBM Level 5
- Therapeutic approaches to Huntington disease: from the bench to the clinic.Nature reviews. Drug discovery 2018 · CEBM Level 5
- The Emerging Evidence of the Parkinson Pandemic.Journal of Parkinson's disease 2018 · CEBM Level 5
- The Best Digital Biomarkers Papers of 2017.Digital biomarkers 2018 · CEBM Level 5
- Virtual visits for Parkinson disease: A multicenter noncontrolled cohort.Neurology. Clinical practice 2017 · CEBM Level 3
- Distribution of Medical Education Debt by Specialty, 2010-2016.JAMA internal medicine 2017 · CEBM Level 4
- Motor, cognitive, and functional declines contribute to a single progressive factor in early HD.Neurology 2017 · CEBM Level 3
- Telehealth Management of Parkinson's Disease Using Wearable Sensors: An Exploratory Study.Digital biomarkers 2017 · CEBM Level 2